Expert Opinion on Drug Metabolism & Toxicology, Volume 14, Issue 12 (2018)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Expert Opinion on Drug Metabolism & Toxicology, Volume 14, Issue 12 (2018)

See all volumes and issues
Vol 20, 2024 Vol 19, 2023 Vol 18, 2022 Vol 17, 2021 Vol 16, 2020 Vol 15, 2019 Volume 14, 2018 Vol 13, 2017 Vol 12, 2016 Vol 11, 2015 Vol 10, 2014 Vol 9, 2013 Vol 8, 2012 Vol 7, 2011 Vol 6, 2010 Vol 5, 2009 Vol 4, 2008 Vol 3, 2007 Vol 2, 2006 Vol 1, 2005
Download citations Download PDFs Download issue

Drug Evaluation

Article
Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson’s disease
Fabrizio Stocchi, Laura Vacca, Paola Stirpe & Margherita Torti
Pages: 1189-1195
Published online: 02 Dec 2018
AbstractforPharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson’s disease | Full Text | References | PDF (714.8 KB)
  • 326 Views
  • 15 CrossRef citations
  • 0Altmetric
Article
Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation
Barbara Deleenheer, Isabel Spriet & Johan Maertens
Pages: 1197-1207
Published online: 04 Dec 2018
AbstractforPharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation | Full Text | References | PDF (1.1 MB)
  • 998 Views
  • 9 CrossRef citations
  • 0Altmetric

Review

Review
Pharmacogenetics of treatments for inflammatory bowel disease
Marianna Lucafò, Raffaella Franca, Davide Selvestrel, Debora Curci, Letizia Pugnetti, Giuliana Decorti & Gabriele Stocco
Pages: 1209-1223
Published online: 03 Dec 2018
AbstractforPharmacogenetics of treatments for inflammatory bowel disease | Full Text | References | PDF (1.2 MB)
  • 441 Views
  • 23 CrossRef citations
  • 0Altmetric
Review
A critical review of adverse effects to the kidney: mechanisms, data sources, and in silico tools to assist prediction
Julia Pletz, Steven J. Enoch, Diviya M. Jais, Claire L. Mellor, Gopal Pawar, James W. Firman, Judith C. Madden, Steven D. Webb, Carlos A. Tagliati & Mark T. D. Cronin
Pages: 1225-1253
Published online: 25 Nov 2018
AbstractforA critical review of adverse effects to the kidney: mechanisms, data sources, and in silico tools to assist prediction | Full Text | References | PDF (2.1 MB) | Supplemental
  • 324 Views
  • 5 CrossRef citations
  • 0Altmetric
Review
Safety and performance of current abuse-deterrent formulations
Rand Ahmad, Samaneh Alaei & Hamid Omidian
Pages: 1255-1271
Published online: 02 Dec 2018
AbstractforSafety and performance of current abuse-deterrent formulations | Full Text | References | PDF (1.3 MB)
  • 307 Views
  • 6 CrossRef citations
  • 0Altmetric
Review
Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure
Mattia Galli, Domenico D’Amario, Carmelo Sofia, Marcello Vaccarella, Filippo Crea & Nadia Aspromonte
Pages: 1273-1285
Published online: 04 Dec 2018
AbstractforClinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure | Full Text | References | PDF (1.2 MB)
  • 645 Views
  • 6 CrossRef citations
  • 0Altmetric
Review
The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments
Alvaro Garcia-Ropero, Juan J. Badimon & Carlos G. Santos-Gallego
Pages: 1287-1302
Published online: 29 Nov 2018
AbstractforThe pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments | Full Text | References | PDF (1.3 MB)
  • 2023 Views
  • 70 CrossRef citations
  • 0Altmetric
Review
How can we best monitor 5-FU administration to maximize benefit to risk ratio?
Françoise Goirand, Florian Lemaitre, Manon Launay, Camille Tron, Etienne Chatelut, Jean-Christophe Boyer, Marc Bardou & Antonin Schmitt
Pages: 1303-1313
Published online: 23 Nov 2018
AbstractforHow can we best monitor 5-FU administration to maximize benefit to risk ratio? | Full Text | References | PDF (980 KB)
  • 642 Views
  • 26 CrossRef citations
  • 0Altmetric
Review
Dose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics
Martyn Howard, Jill Barber, Naved Alizai & Amin Rostami-Hodjegan
Pages: 1315-1330
Published online: 22 Nov 2018
AbstractforDose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics | Full Text | References | PDF (1.8 MB)
  • 314 Views
  • 9 CrossRef citations
  • 0Altmetric

Explore articles

Explore the most recently published articles

Genetic polymorphisms of drug-metabolizing enzymes in older and newer anti-seizure medications
Gianluca D’Onofrio et al.
Editorial | Published online: 31 May 2024
Free Access
Understanding the impact of ABCG2 Polymorphisms on Drug Pharmacokinetics:Focus on rosuvastatin and allopurinol
Anne Kasten et al.
Review Article | Published online: 29 May 2024
Recent progress in machine learning approaches for predicting carcinogenicity in drug development
Nguyen Quoc Khanh Le et al.
Review Article | Published online: 27 May 2024
New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact
Lorenzo Gasperoni et al.
Review Article | Published online: 22 May 2024
Open Access
View all latest articles